Jecure
WebFounders Ariel Feldstein. Operating Status Active. Last Funding Type Series A. Company Type For Profit. Contact Email [email protected]. Phone Number (888) 888-8888. … Web29 nov 2024 · Jecure has a preclinical portfolio of NLRP-3 class drugs used to treat inflammatory and autoimmune disorders such as NASH, liver fibrosis, gout, inflammatory …
Jecure
Did you know?
WebJecure Therapeutics, Inc. 1 DNA way South San Francisco CA 94080 United States. Web: ... WebRoche has joined the melee of pharma companies trying to claim a share of the market for non-alcoholic steatohepatitis (NASH) drugs, cutting a deal to acquire US start-up Jecure Therapeutics. Terms of the takeover haven’t been disclosed, but buying the San Diego biotech will give Roche rights to its portfolio of NLRP3 inhibitors, all currently at the …
Web29 nov 2024 · Roche’s subsidiary, Genentech will obtain full rights to Jecure’s entire preclinical portfolio of NLRP3 inhibitors. The latter began operating in 2015 following a seed financing from founding ... Web15 feb 2024 · Jecure reunites Stafford and James Veal, biotech entrepreneurs who previously started another Versant-backed firm, Quanticel Pharmaceuticals. Celgene bought that cancer-focused company in 2015 ...
Web开馆时间：周一至周日7:00-22:30 周五 7:00-12:00; 我的图书馆 Web7 dic 2024 · Register to receive a free Global Immunology Drugs Market Report Suite 2024-2024 report synopsis and brochure Jecure Therapeutics Inc., a biotechnology company with novel drug discovery programs targeting serious inflammatory diseases, announced a definitive agreement by which it will be acquired by Genentech, a member of the Roche …
Web15 feb 2024 · Jecure is focused on the discovery of novel therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) and liver fibrosis. Jecure’s scientific founder is Dr. …
Web28 nov 2024 · Roche group Genentech is acquiring San Diego-based biotech Jecure Therapeutics. Jecure specialises in a wide range of inflammatory and autoimmune disorders, such as non-alcoholic steatohepatitis (NASH), liver fibrosis, gout, inflammatory bowel disease and cardiovascular diseases, and is developing NLRP3 inhibitors to fight … brackenridge park train san antonioWeb29 nov 2024 · Roche is apparently the latest entrant and will be aiming to turn Jecure Therapeutics’ research into drugs for the purpose. Reportedly, Jecure will give its preclinical portfolio of NLRP3 inhibitors that are still under development to fighting inflammatory diseases which include not only NASH but also liver fibrosis, gout, cardiovascular … h20 fitness collaborativeWeb25 feb 2024 · 09:42 РБК: Россиян стали приглашать на работу в другие страны в полтора раза чаще; 07:30 Microsoft прекратил гарантийное обслуживание всех консолей Xbox в России; 01:25 В Чехии спрогнозировали … h20 fish feverWeb28 nov 2024 · “The acquisition of Jecure provides a unique opportunity to bring novel NLRP3 inhibitors to patients.” Roche’s global head of Pharma Partnering James Sabry added the firm is “excited to combine Jecure’s portfolio with our discovery and development capabilities, as well as our expertise in NLRP3 biology, to potentially help people with … bracken ridge property growthWebVersant seeded Jecure as part of the firm’s push to build on its past success in the fibrosis field, and was the sole investor in today’s $20 million series A commitment. Jecure’s founding team includes CEO Jeffrey Stafford, PhD, and CSO James Veal, PhD, both of bracken ridge pump trackWebJecure Therapeutics, Inc. operates as a biotechnology company. The Company focuses on discovery and development of novel therapeutics for the treatment of NASH and liver … bracken ridge plaza shopping centreWeb27 nov 2024 · Swiss drugmaker Roche is buying U.S.-based Jecure Therapeutics, joining Pfizer, Gilead Sciences and Novartis in pursuit of new drugs to treat fatty liver disease. bracken ridge ranch